United StatesHealth

Teva Pharmaceuticals (NYSE:TEVA) announced that the U.S. FDA accepted its New Drug Application for ecopipam (EBS-101) and granted Priority Review for pediatric Tourette syndrome.

Intelligent Bio Solutions (NASDAQ:INBS) reported fiscal 2026 revenue of $4.2 million, up 38% year over year, driven by growth in its installed reader base and consumable cartridge sales.

Chemomab Therapeutics (NASDAQ:CMMB) reported second-quarter 2026 results and progress on its proposed all-stock merger with Scipher Medicine, with Chemomab shareholders expected to own about 32% of a combined company valued at $150 million.

Galmed Pharmaceuticals (NASDAQ:GLMD) announced that its wholly owned subsidiary Colospan completed a first-in-human feasibility study of a colon tissue quality assessment platform in 32 colorectal cancer patients undergoing elective surgery.

Merck (NYSE:MRK) and Moderna (NASDAQ:MRNA) announced positive Phase 3 results from the INTerpath-001 trial, with intismeran autogene combined with KEYTRUDA meeting its primary recurrence-free survival endpoint and key secondary distant metastasis-free survival endpoint in patients with resected stage IIB-IV melanoma.

IDEAYA Biosciences (NASDAQ:IDYA) announced a clinical collaboration with Genentech to evaluate IDE892 with GDC-7035 (RG6620) in patients with MTAP-deleted, KRAS G12D-mutant pancreatic ductal adenocarcinoma (PDAC).

FORT Robotics agreed to combine with Newbury Street II Acquisition Corp (NASDAQ:NTWO) at a $556.6 million pro forma enterprise value, with the combined company expected to trade as FROB.

BlossomHill Therapeutics (NASDAQ:BLSM) received FDA Fast Track designation for BH-30643 in adults with advanced or metastatic EGFR C797S-positive non-small cell lung cancer.

Immatics (NASDAQ:IMTX) reported Q2 2026 collaboration revenue of $10.4 million, up from $5.4 million, while its net loss narrowed to $71.2 million.

Amylyx Pharmaceuticals (NASDAQ:AMLX) said avexitide met the Phase 3 LUCIDITY primary endpoint with a 55% reduction in Level 2 and Level 3 hypoglycemic events versus placebo.

Evogene (NASDAQ:EVGN) reported a Q2 2026 net loss of approximately $1.8 million, narrowing from about $4.7 million in the prior-year quarter.